IRMD

SEC source: 0001415889-25-010210 · form4-04042025_040401.xml · derivative · entry 3

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,592

Underlying: Common Stock · 5,796 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents shares of common stock that the Reporting Peron received upon the vesting of restricted stock units ("RSUs") on a one-for-one basis.

F3 · derivative.exercise_date: The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

F3 · derivative.expiration_date: The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001415889-25-010210 · form4-04042025_040401.xml · nonDerivative · entry 2

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,767

F2 · shares: The transaction was inadvertently reported late. The aggregate amount of securities beneficially owned includes the delinquent transaction plus all transactions reported in Form 4's filed after the date of the delinquent transaction.

SEC source: 0001415889-25-010210 · form4-04042025_040401.xml · nonDerivative · entry 1

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,179

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents shares of common stock that the Reporting Peron received upon the vesting of restricted stock units ("RSUs") on a one-for-one basis.

F2 · shares: The transaction was inadvertently reported late. The aggregate amount of securities beneficially owned includes the delinquent transaction plus all transactions reported in Form 4's filed after the date of the delinquent transaction.

F1 · price: Represents shares of common stock that the Reporting Peron received upon the vesting of restricted stock units ("RSUs") on a one-for-one basis.

SEC source: 0001415889-25-010289 · form4a-04072025_040401.xml · derivative · entry 1

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,592

Underlying: Common Stock · 5,796 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: When vested, restricted stock units ("RSUs") are convertible into common stock on a one-for-one basis.

F2 · shares: On April 4, 2025, the Reporting Person filed a Form 4, which inadvertently stated in Column 5 of Table II that 5,796 RSUs were acquired instead of disposed. This inadvertent misstatement has been corrected in this amended filing to note that 5,796 RSUs were disposed.

F3 · derivative.exercise_date: On June 20, 2022, the Reporting Person received RSUs under Iradimed Corporation's 2014 Equity Incentive Plan. The RSUs vest in four equal annual installments beginning on June 20, 2023. Upon vesting, the Reporting Person will receive a number of shares of common stock equal to the number of RSUs that have vested.

F3 · derivative.expiration_date: On June 20, 2022, the Reporting Person received RSUs under Iradimed Corporation's 2014 Equity Incentive Plan. The RSUs vest in four equal annual installments beginning on June 20, 2023. Upon vesting, the Reporting Person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001415889-24-015408 · form4-06042024_050601.xml · nonDerivative · entry 1

ALLEN MONTY K · CIK 0001253352 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,053

F1 · price: This transaction was executed in multiple trades at prices ranging from $43.17 to $43.37. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-016965 · form4-12272023_061201.xml · nonDerivative · entry 2

Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Roger E. Susi Revocable Trust

Disclosed balance after: 162,950

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $46.50 to $46.67. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-016965 · form4-12272023_061201.xml · nonDerivative · entry 1

Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Roger E. Susi Revocable Trust

Disclosed balance after: 167,950

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023.

SEC source: 0001415889-23-016907 · form4-12222023_051202.xml · nonDerivative · entry 1

Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Matthew Susi 2008 Dynasty Trust

Disclosed balance after: 2,062,500

F1 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-23-016785 · form4-12202023_041201.xml · nonDerivative · entry 2

Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Roger E. Susi Revocable Trust

Disclosed balance after: 172,950

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023.

F3 · price: This transaction was executed in multiple trades at prices ranging from $43.80 to $45.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-016785 · form4-12202023_041201.xml · nonDerivative · entry 1

Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Roger E. Susi Revocable Trust

Disclosed balance after: 177,950

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $43.33 to $45.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-016502 · form4-12142023_081201.xml · derivative · entry 15

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,277 shares

Expires 2024-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option, representing a right to purchase a total of 10,000 shares, was granted on 12-15-2014 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date.

F3 · derivative.expiration_date: This option, representing a right to purchase a total of 10,000 shares, was granted on 12-15-2014 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date.

SEC source: 0001415889-23-016502 · form4-12142023_081201.xml · nonDerivative · entry 10

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,348

F5 · price: This transaction was executed in multiple trades at prices ranging from $44.50 to $44.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-016502 · form4-12142023_081201.xml · nonDerivative · entry 9

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,625

F3 · price: This option, representing a right to purchase a total of 10,000 shares, was granted on 12-15-2014 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date.

SEC source: 0001415889-23-016502 · form4-12142023_081201.xml · derivative · entry 14

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,277

Underlying: Common Stock · 219 shares

Expires 2024-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option, representing a right to purchase a total of 10,000 shares, was granted on 12-15-2014 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date.

F3 · derivative.expiration_date: This option, representing a right to purchase a total of 10,000 shares, was granted on 12-15-2014 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date.

SEC source: 0001415889-23-016502 · form4-12142023_081201.xml · derivative · entry 13

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,496

Underlying: Common Stock · 5,000 shares

Expires 2024-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option, representing a right to purchase a total of 10,000 shares, was granted on 12-15-2014 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date.

F3 · derivative.expiration_date: This option, representing a right to purchase a total of 10,000 shares, was granted on 12-15-2014 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date.

SEC source: 0001415889-23-016502 · form4-12142023_081201.xml · nonDerivative · entry 8

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,348

F4 · price: This transaction was executed in multiple trades at prices ranging from $42.25 to $43.67. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-016502 · form4-12142023_081201.xml · nonDerivative · entry 7

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,567

F3 · price: This option, representing a right to purchase a total of 10,000 shares, was granted on 12-15-2014 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date.

SEC source: 0001415889-23-016502 · form4-12142023_081201.xml · nonDerivative · entry 6

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,348

F4 · price: This transaction was executed in multiple trades at prices ranging from $42.25 to $43.67. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-016502 · form4-12142023_081201.xml · nonDerivative · entry 5

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,348

F3 · price: This option, representing a right to purchase a total of 10,000 shares, was granted on 12-15-2014 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date.

SEC source: 0001415889-23-016362 · form4-12132023_041205.xml · nonDerivative · entry 2

Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Roger E. Susi Revocable Trust

Disclosed balance after: 182,950

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023.

F3 · price: This transaction was executed in multiple trades at prices ranging from $41.17 to $43.58. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-016502 · form4-12142023_081201.xml · derivative · entry 12

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,496

Underlying: Common Stock · 504 shares

Expires 2024-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option, representing a right to purchase a total of 10,000 shares, was granted on 12-15-2014 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date.

F3 · derivative.expiration_date: This option, representing a right to purchase a total of 10,000 shares, was granted on 12-15-2014 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date.

SEC source: 0001415889-23-016502 · form4-12142023_081201.xml · derivative · entry 11

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 468 shares

Expires 2024-09-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option, representing a right to purchase a total of 10,000 shares, was granted on 9-29-2014 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date.

SEC source: 0001415889-23-016502 · form4-12142023_081201.xml · nonDerivative · entry 4

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,348

F2 · price: This transaction was executed in multiple trades at prices ranging from $43.25 to $43.59. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-016502 · form4-12142023_081201.xml · nonDerivative · entry 3

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,852

F3 · price: This option, representing a right to purchase a total of 10,000 shares, was granted on 12-15-2014 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date.

SEC source: 0001415889-23-016502 · form4-12142023_081201.xml · nonDerivative · entry 2

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,348

F2 · price: This transaction was executed in multiple trades at prices ranging from $43.25 to $43.59. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-016502 · form4-12142023_081201.xml · nonDerivative · entry 1

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,816

F1 · price: This option, representing a right to purchase a total of 10,000 shares, was granted on 9-29-2014 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date.

SEC source: 0001415889-23-016362 · form4-12132023_041205.xml · nonDerivative · entry 1

Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Roger E. Susi Revocable Trust

Disclosed balance after: 187,950

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $40.50 to $41.83. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-016249 · form4-12112023_061202.xml · derivative · entry 5

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,144

Underlying: Common Stock · 2,393 shares

Expires not disclosed

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F4 · derivative.exercise_date: On December 7, 2023, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2024. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F4 · derivative.expiration_date: On December 7, 2023, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2024. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001415889-23-016249 · form4-12112023_061202.xml · derivative · entry 4

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,751

Underlying: Common Stock · 1,750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: On December 7, 2022, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F3 · derivative.expiration_date: On December 7, 2022, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001415889-23-016249 · form4-12112023_061202.xml · derivative · entry 3

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,036 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: On December 7, 2021, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2022. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F2 · derivative.expiration_date: On December 7, 2021, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2022. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001415889-23-016249 · form4-12112023_061202.xml · nonDerivative · entry 2

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,348

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0001415889-23-016249 · form4-12112023_061202.xml · nonDerivative · entry 1

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,598

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0001415889-23-016253 · form4-12112023_061212.xml · derivative · entry 2

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,684

Underlying: Common Stock · 7,180 shares

Expires not disclosed

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: The reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2014 Equity Incentive Plan. Vesting of these PRSUs depends on the reporting person's achievement of specified relative ranking of total shareholder return over a three-year period from December 8, 2023 through December 7, 2026.

F4 · derivative.exercise_date: If the relative measure at December 7, 2026 and for the three-year period then ended is: (i) less than or equal to 80% of the peer group, no vesting would occur, (ii) between 80% and 100% of the peer group, the number of shares vesting would be pro-rata against the nominal granted shares, (iii) equal to 100% of the peer group, the number of shares vesting would be the nominal granted shares, (iv) between 100%and 120% of the peer group, the number of shares vesting would be pro-rata against an additional tranche of the nominal granted shares plus the nominal granted shares, and (v) if 120% or greater of the peer group, the number of shares vesting would be double the nominal granted shares.

F5 · derivative.exercise_date: Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of PRSUs that have vested.

F3 · derivative.expiration_date: The reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2014 Equity Incentive Plan. Vesting of these PRSUs depends on the reporting person's achievement of specified relative ranking of total shareholder return over a three-year period from December 8, 2023 through December 7, 2026.

F4 · derivative.expiration_date: If the relative measure at December 7, 2026 and for the three-year period then ended is: (i) less than or equal to 80% of the peer group, no vesting would occur, (ii) between 80% and 100% of the peer group, the number of shares vesting would be pro-rata against the nominal granted shares, (iii) equal to 100% of the peer group, the number of shares vesting would be the nominal granted shares, (iv) between 100%and 120% of the peer group, the number of shares vesting would be pro-rata against an additional tranche of the nominal granted shares plus the nominal granted shares, and (v) if 120% or greater of the peer group, the number of shares vesting would be double the nominal granted shares.

F5 · derivative.expiration_date: Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of PRSUs that have vested.

SEC source: 0001415889-23-016253 · form4-12112023_061212.xml · derivative · entry 1

GLENN JOHN · CIK 0001253497 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,072

Underlying: Common Stock · 7,180 shares

Expires not disclosed

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: The reporting person received restricted stock units ("RSUs") under Iradimed Corporation's 2014 Equity Incentive Plan. The RSUs vest in full on the third anniversary of the grant date, December 7, 2026. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

F2 · derivative.expiration_date: The reporting person received restricted stock units ("RSUs") under Iradimed Corporation's 2014 Equity Incentive Plan. The RSUs vest in full on the third anniversary of the grant date, December 7, 2026. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001415889-23-016252 · form4-12112023_061210.xml · derivative · entry 1

Scharen-Guivel Hilda Frederique · CIK 0001950129 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,393

Underlying: Common Stock · 2,393 shares

Expires not disclosed

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: On December 7, 2023, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2024. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F2 · derivative.expiration_date: On December 7, 2023, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2024. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001415889-23-016251 · form4-12112023_061207.xml · derivative · entry 5

VUOTO ANTHONY · CIK 0001222060 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,144

Underlying: Common Stock · 2,393 shares

Expires not disclosed

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F4 · derivative.exercise_date: On December 7, 2023, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2024. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F4 · derivative.expiration_date: On December 7, 2023, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2024. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001415889-23-016251 · form4-12112023_061207.xml · derivative · entry 4

VUOTO ANTHONY · CIK 0001222060 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,751

Underlying: Common Stock · 1,750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: On December 7, 2022, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F3 · derivative.expiration_date: On December 7, 2022, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001415889-23-016251 · form4-12112023_061207.xml · derivative · entry 3

VUOTO ANTHONY · CIK 0001222060 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,036 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: On December 7, 2021, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2022. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F2 · derivative.expiration_date: On December 7, 2021, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2022. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001415889-23-016251 · form4-12112023_061207.xml · nonDerivative · entry 2

VUOTO ANTHONY · CIK 0001222060 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,924

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0001415889-23-016251 · form4-12112023_061207.xml · nonDerivative · entry 1

VUOTO ANTHONY · CIK 0001222060 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,174

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0001415889-23-016250 · form4-12112023_061205.xml · derivative · entry 5

ALLEN MONTY K · CIK 0001253352 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,144

Underlying: Common Stock · 2,393 shares

Expires not disclosed

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F4 · derivative.exercise_date: On December 7, 2023, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2024. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F4 · derivative.expiration_date: On December 7, 2023, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2024. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001415889-23-016250 · form4-12112023_061205.xml · derivative · entry 4

ALLEN MONTY K · CIK 0001253352 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,751

Underlying: Common Stock · 1,750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: On December 7, 2022, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F3 · derivative.expiration_date: On December 7, 2022, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001415889-23-016250 · form4-12112023_061205.xml · derivative · entry 3

ALLEN MONTY K · CIK 0001253352 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,036 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: On December 7, 2021, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2022. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F2 · derivative.expiration_date: On December 7, 2021, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2022. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001415889-23-016250 · form4-12112023_061205.xml · nonDerivative · entry 2

ALLEN MONTY K · CIK 0001253352 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0001415889-23-016250 · form4-12112023_061205.xml · nonDerivative · entry 1

ALLEN MONTY K · CIK 0001253352 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,250

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0001415889-23-015924 · form4-12062023_041202.xml · nonDerivative · entry 2

Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Roger E. Susi Revocable Trust

Disclosed balance after: 192,950

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023.

F3 · price: This transaction was executed in multiple trades at prices ranging from $40.67 to $42.28. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-015865 · form4-12052023_041221.xml · derivative · entry 6

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 468

Underlying: Common Stock · 4,273 shares

Expires 2024-09-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option, representing a right to purchase a total of 10,000 shares, was granted on 9-29-2014 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date.

SEC source: 0001415889-23-015865 · form4-12052023_041221.xml · nonDerivative · entry 4

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,562

F3 · price: This transaction was executed in multiple trades at prices ranging from $42.70 to $42.78. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-015865 · form4-12052023_041221.xml · nonDerivative · entry 3

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,835

F1 · price: This option, representing a right to purchase a total of 10,000 shares, was granted on 9-29-2014 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date.

SEC source: 0001415889-23-015924 · form4-12062023_041202.xml · nonDerivative · entry 1

Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Roger E. Susi Revocable Trust

Disclosed balance after: 197,950

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $42.00 to $42.45. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.